Abstract Neuromyelitis Optica (NMO) is a rare neuroinflammatory disorder with limited epidemiological data. Antibodies against aquaporin-4 (Aq4ab) are reported to be highly specific for NMO and NMO spectrum disorders (NMO-SD).
The antibody suspension bead array technology has been shown to be highly applicable for discovery of potential biomarkers in blood derived samples [1]. For analysis in neurodegenerative disorders like multiple sclerosis (MS), cerebrospinal fluid (CSF) is another highly interesting body fluid for protein profiling efforts [2].
Objectives: Neuromyelitis optica (NMO) is an uncommon but life-threatening demyelinating disorder. With the discovery of the NMO antibody in 2004, diagnostic criteria have been revised